Caroline Seymour


Frontline Durvalumab Does Not Elicit Significant OS Improvement in Advanced, PD-L1-High NSCLC

December 29, 2022

In the PEARL trial, monotherapy with durvalumab did not deliver a statistically significant improvement in overall survival vs platinum-based chemotherapy as frontline treatment in patients with PD-L1-high stage IV non–small cell lung cancer.

5-Year Findings Support Xevinapant Plus Chemotherapy in Locally Advanced Head and Neck Cancer

October 28, 2022

A presentation at the 2022 ESMO Congress found that xevinapant plus chemoradiotherapy decreased the risk of death by twice that of placebo for patients with unresectable, locally advanced head and neck squamous cell carcinoma.

Frontline Ibrutinib Plus Venetoclax Reduces Relapse in Elderly Patients with Chronic Lymphocytic Leukemia

October 15, 2022

A subgroup of the phase 3 GLOW trial revealed a unique relationship between undetectable minimal residual disease status and progression-free survival in elderly or unfit patients with chronic lymphocytic leukemia who received ibrutinib plus venetoclax.